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Abstract: BACKGROUND: The injection of muscle precursor cells (MPC) into the external urinary
sphincter muscle (EUS) is a promising therapeutic option for regenerative treatment of stress urinary
incontinence (SUI). The objective of the present project was to conduct a pre-clinical trial to investigate
the feasibility and accuracy of ultrasound (US) guided, transurethral injections into the EUS of female
cadavers. METHODS: This is a prospective, anatomical, interventional and radiological cadaveric lab-
oratory investigation. Two urologists performed transurethral US-guided injections to deliver nano-iron
particles into the EUS. The intervention was performed in three unfixed, fresh female cadavers. Each
cadaver received MRI before and CT as well as MRI of the pelvis after the injections. RESULTS: The
precision and accumulation of nano-iron particles in the EUS was compared using a rating scale to eval-
uate left versus right and anterior versus posterior distribution in axial and sagittal orientation with
US, MRI and CT. The accuracy of our US-guided injections into the anterior target region yielded 4
points on the rating scale. Adequate precision and accumulation of particles in the left versus right
EUS were also demonstrated (3 vs. 3.33 points, respectively). Signal intensity in MRI revealed a mean
ratio of 0.33 before and after injection. CT scans showed no relevant artefacts impairing the assessment.
CONCLUSION: US-guided, transurethral injection into the EUS is feasible and imaging reveals a precise
accumulation in the target region. Our method provides an appropriate approach to deliver MPC in the
EUS muscle for a regenerative treatment of SUI in the near future.
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Feasibility, technique and accuracy 
of ultrasound-guided transurethral injections 
into the urinary sphincter of female cadavers: 
proof of concept
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and Daniel Eberli1*
Abstract 
Background: The injection of muscle precursor cells (MPC) into the external urinary sphincter muscle (EUS) is a 
promising therapeutic option for regenerative treatment of stress urinary incontinence (SUI). The objective of the 
present project was to conduct a pre-clinical trial to investigate the feasibility and accuracy of ultrasound (US) guided, 
transurethral injections into the EUS of female cadavers.
Methods: This is a prospective, anatomical, interventional and radiological cadaveric laboratory investigation. Two 
urologists performed transurethral US-guided injections to deliver nano-iron particles into the EUS. The intervention 
was performed in three unfixed, fresh female cadavers. Each cadaver received MRI before and CT as well as MRI of the 
pelvis after the injections.
Results: The precision and accumulation of nano-iron particles in the EUS was compared using a rating scale to 
evaluate left versus right and anterior versus posterior distribution in axial and sagittal orientation with US, MRI and 
CT. The accuracy of our US-guided injections into the anterior target region yielded 4 points on the rating scale. 
Adequate precision and accumulation of particles in the left versus right EUS were also demonstrated (3 vs. 3.33 
points, respectively). Signal intensity in MRI revealed a mean ratio of 0.33 before and after injection. CT scans showed 
no relevant artefacts impairing the assessment.
Conclusion: US-guided, transurethral injection into the EUS is feasible and imaging reveals a precise accumulation in 
the target region. Our method provides an appropriate approach to deliver MPC in the EUS muscle for a regenerative 
treatment of SUI in the near future.
Keywords: Transurethral injection, Urinary sphincter, Ultrasound-guided, MRI, Female
© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco 
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Stress Urinary Incontinence (SUI) is a disease affect-
ing almost 200 million people worldwide and is twice 
as common in women as in men [1]. The quality of life 
in these patients is markedly decreased due to reduced 
activity, unpleasant sensation and odor as well as recur-
rent urinary tract infections caused by wet pads [2, 3]. 
Several therapeutic options exist in the treatment of SUI: 
Besides physiotherapy of the lower pelvis, various medi-
cal, mechanical and surgical approaches can be discussed 
with the patients [4–8]. However, all of these therapies 
have limitations and new solutions with long-term effects 
are needed. The regenerative approach, administering 
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muscle precursor cells (MPC), is a promising new strat-
egy to strengthen the external urinary sphincter mus-
cle (EUS) in a sustainable manner in patients with SUI 
[9–11]. Pursuing the ultimate goal of treating the cause 
rather than the symptom was already convincing in the 
animal model, and the translation of this therapy into 
humans demonstrated first promising results in the past 
[12, 13]. However, particularly the precise deliverance of 
MPCs into the target region is a challenging endeavor. 
Stem cells are highly influenced by the microenvironment 
and therefore an accurate injection into the external EUS 
is required. The aim of the present study was to prove the 
feasibility and precision of a new ultrasound (US) guided 
transurethral injection technique into the EUS.
Methods
In this prospective, anatomical, interventional and radio-
logical cadaveric laboratory investigation, we included 
three unfixed, fresh female cadavers for research pur-
poses between May 2019 and January 2020. As initial 
baseline investigation, a radiological technologist per-
formed magnetic resonance imaging (MRI) of the lower 
pelvis at the Institute of Forensic Medicine shortly after 
arrival of the cadaver. Before, the cadaveric bodies were 
stored at 4 °C for a maximum of 72 h. After imaging, we 
transported the bodies to the “Skills Laboratory” of the 
Institute of Anatomy and put them into lithotomy posi-
tion. The lower pelvis was investigated by initial vagi-
nal US carried out by two urologists, performing a 3D 
block of the lower pelvis. This allowed the identification 
of important anatomical landmarks and the location of 
the EUS in mid-urethral position as a hypoechoic struc-
ture. The next step was the insertion of a transurethral 
indwelling bladder catheter (12 French) and the filling 
of the catheter balloon with 10  ml (ml) of saline solu-
tion. Further, a urethral therapy (stainless steel) shaft was 
attached to the catheter outside of the urethral meatus. 
After filling of the bladder with 100 ml of saline solution, 
we attached a Kochers’ clamp at the rear of the catheter 
to prevent outflow. Further, this assured fixation of the 
catheter balloon at the bladder neck as an anatomical 
reference structure. We then reassured a good position 
of the vaginal US probe and double-checked image qual-
ity. Thereafter, the urethral therapy shaft was inserted 
into the urethral meatus in Seldinger technique along 
the transurethral catheter until mid-urethral position 
and then linked to the vaginal ultrasound probe. This led 
to a signal loss in the distal part of the US image. After 
bringing in a puncture cannula through the therapy shaft, 
the tip of the needle was identified in the target region 
at 12 o’clock position. The needle was then adapted to 
a syringe with a cooled solution of 4  ml nano-iron par-
ticles (Endorem®, Guerbet AG, dextran-coated SPIO 
nanoparticles, size distribution 120–180  nm, iron-
content 11.2  mg/ml), that was transported to the facil-
ity of the Anatomical Institute in a refrigerated box. For 
the injection in cadaver 1, the nano iron-particles were 
used in the above-mentioned, original dosage. Due to 
a massive extinction signal in cadaver 1 (Additional 
file 1: Appendix, Figs.  4 and 5), we diluted the particles 
in a 1:100 manner with saline solution for cadavers 2–3 
(Additional file 1: Appendix, Figs. 4 and 5). Further, the 
nano-iron particles were mixed with a collagen solu-
tion. Collagen changes its viscosity with increasing tem-
perature and turns into a jelly composition. Therefore, 
an out- or backflow of the injection mixture through the 
puncture canal can be minimized in living humans. How-
ever, because the cadavers had to be stored in the fridge 
at 4  °C, this effect was only minimal. We started with 
the first injection at the 12 o’clock position and changed 
the angle gradually to the right or to the left for each of 
the subsequent injections. It was our intention to focus 
mainly on anterior injection, since the EUS has an inverse 
“horseshoe” configuration. At the end of the procedure, 
all of the instruments were removed. Back at the Institute 
of Forensic Medicine, each of the female corpses received 
a second MRI of the pelvis in order to compare the 
acquired images to those before the injection. Further, a 
computer tomography (CT) examination was performed 
to exclude artefacts in the region of interest, such as the 
presence of air bubbles caused by the injection. Air bub-
bles would alter the signal-intensity (SI) in MRI, whereas 
the quality of evaluation would be limited.
MRI and CT scanning protocol
The MRI examination was performed using a 3  T MRI 
unit (Achieva 3.0 TX, Philips Medical System, Best, The 
Netherlands) and a 16 elements phased-array SENSE XL 
Torso coil. The scan protocol included a T1-weighted 
turbo-spin-echo (TSE) sequence (orientation: transver-
sal; TR: 578 ms; TE: 6.8 ms; acquisition voxel size [mm]: 
0.7 × 0.7 × 2.5), T2-weighted TSE sequences (orientation: 
transversal/coronal/sagittal; TR: 3765/3464/1958  ms; 
TE: 60  ms; acquisition voxel size [mm]: 0.8 × 0.8 × 2.5), 
and T2*-(susceptibility-) weighted fast-field-echo (FFE) 
sequences (orientation: transversal/coronal; TR: 1117 ms; 
TE: 16  ms; acquisition voxel size [mm]: 0.9 × 1.2 × 2.5). 
The same MRI scanning protocol was used before and 
after the injection of the nano-iron particles.
The CT scans were performed using a 128-slice CT 
(SOMATOM Definition Flash, Siemens Healthcare, 
Forchheim, Germany). First, a CT scan over the entire 
pelvis was performed. The scan parameters were 120 kVp, 
800 mAs, and a pitch of 0.35. The raw data were recon-
structed using a slice thickness of 0.6 with a hard kernel 
(B60) and a soft kernel (B30). Second, a high-resolution 
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CT over the region of the sphincter was performed using 
120 kVp, 330 mAs, and a pitch of 0.35. Reconstructions 
were calculated using small field-of-view (50 × 50  mm; 
pixel spacing (in-plane voxel): 0.098  mm) with a slice 
thickness of 0.4 mm and a hard kernel (U70) [14].
Evaluation of imaging
Baseline MRI and an US 3D-block of the lower pelvis 
assessed the status quo and the exact anatomy before 
injection (Fig.  1a, b). US was then used as guidance 
and documentation of the whole injection procedure 
(Figs.  1c, d, 2a). The MRI and the additional CT scan 
after the injections were performed for the analysis of 
injection precision (Fig.  2b–d). With three different 
imaging modalities (US, MRI and CT), we were able to 
compare injection accuracy in an objective and quali-
tative way. We rated the precision of our injections 
according to a rating scale from 1–4 points: 1 = center 
(diameter/distance = 5  mm), 2 = inner ring/line (diam-
eter/distance = 10  mm), 3 = middle ring/line (diameter/
distance = 15  mm), 4 = outer ring/line (diameter/dis-
tance > 15 mm). For the evaluation, images were divided 
into left/right in axial as well as anterior/posterior in 
sagittal orientation (Fig. 2c, d). With this scoring system, 
the accuracy of injections through imaging was evaluated 
by the consensus of two independent raters (radiological 
Fig. 1 a Anatomy of the lower female pelvis in 3D US with transversal view and b MRI T2 sequence in axial view. c Setting before transurethral 
injection of nano-iron particles. Extracorporeal setup, where vaginal US probe and urethral therapy shaft are linked together. d Needle puncture and 
injection are performed through the therapy shaft
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technologist and urologist). The cumulative extinction 
signal in both orientations (sagittal and axial) was calcu-
lated as 3D-volumes. Additionally, we evaluated signal-
intensity changes in MRI: According to signal-intensity 
curves (Fig. 3a, b, Additional file 1: Appendix Figs. 6 and 
7), the ratio before and after injection of diluted nano-
iron particles was calculated for the EUS region. To do so, 
standard protocols were used.
Results
In each of the cadavers, all three imaging modalities—
US, MRI and CT—were applied. In MRI, we have quali-
tatively evaluated the sharpness and details of the images 
for the inspection and extension of small muscle struc-
tures, such as the EUS muscle. Image quality was evenly 
distributed among all of the cadavers, except for arte-
facts in cadaver 2 due to bilateral hip prosthesis. How-
ever, these artifacts did not impede measurements on the 
rating sale; thus, this cadaver was not excluded. Further, 
the fixation of an US-probe to the therapy shaft and the 
subsequent imaging quality was of relevance and did not 
differ among cadavers. Additionally, it was important to 
evaluate the impact of ventral artefacts after inserting the 
urethral therapy shaft (metal composition) and to assess 
whether the needle could still be tracked precisely, which 
was the case in all three interventions. As described in 
the methods section, our injectable solution of nano-iron 
particles and collagen needed to be diluted with saline 
after the first procedure, due to strong extinction signals 
in cadaver 1 (Additional file 1: Appendix, Figs. 4 and 5). 
However, since the center of the extinction signal was in 
the right anatomical location, cadaver 1 was not excluded 
from the analysis. In total, the MRI revealed the loca-
tion of our injections precisely at intended mid-urethral 
and anterior position (Additional file 1: Appendix, Figs. 4 
and 5). CT scans additionally assured the absence of air 
Fig. 2 a US image in sagittal orientation during transurethral injection. b MRI image in axial orientation after injection of nano-iron particles. c, d 
Scoring of injection defined on a rating scale from 1 to 4 points according to extinction signal of injected iron nano-particles in MRI images. c Axial 
orientation with division into right and left, d sagittal orientation with division into anterior and posterior. Diameter and distances in (a) and (b), 
respectively: 1 = 5 mm, 2 = 10 mm, 3 = 15 mm, 4 > 15 mm
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bubbles in the area of injection (Additional file 1: Appen-
dix, Figs. 4 and 5). The handling of the needle, assuring 
the correct depth of puncture and the equal distribution 
of the 4  ml solution through all the intended injections 
spots were feasible at all times. The assessment of injec-
tion location revealed a maximum score of 4 points on 
the rating scale in anterior orientation and comparable 
results regarding division of the injection volume were 
obtained left vs. right (3 vs. 3.33 points). The lowest 
amount was seen in the posterior region with a mean 
rating score of 2.67 points. The mean injection volume 
calculated by the MRI was 1.75 cm3 (Table 1). The meas-
urement of the MRI extinction signal revealed a signal-
intensity (SI) curve with a consistent ratio of less than a 
half (mean SI-ratio = 0.33) before and after injection of 
nano-iron particles into the EUS (reference SI: air ≈ 0, 
purefat ≈ 1500) (Table 1).
Fig. 3 Evaluation of the ratio of signal intensity in the EUS muscle in MRI. Measured differences due to extinction before and after injection of 
nano-iron particles in Cadaver 3. The red area marks the EUS in all parts of the figure. a Overall, b zoom
Table 1 Scores per  cadaver on  the  rating scale according to  extinction signal in  MRI image in  axial (left, right) 
and sagittal (anterior, posterior) orientation
Measured radius, area and volume of injection. Signal-intensity ratio before and after injection in the EUS
SI signal-intensity, MR magnetic resonance








1 4 4 4 4 4 2.5 19.6 3.82 0.055
2 2 4 4 1 2.75 5.0 78.5 0.32 0.526
3 3 2 4 3 3 7.5 176.7 1.11 0.404
Column mean 3 3.33 4 2.67 3.25 5 91.60 1.75 0.33
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Discussion
In the present study, we were able to prove that our tech-
nique for transurethral injections into the EUS under US 
guidance is feasible and yields good precision as seen in 
subsequent imaging proof. The signal decrease in pelvis 
MRI demonstrates a mean ratio of 0.33 when compar-
ing intensities before and after the injection of nano-iron 
particles into the EUS. The indication for the use of nano-
iron particles (SPIO = superparamagnetic iron oxide) in 
clinical MRI became broad over the last years, but was 
initially intended for the enhanced identification of focal 
malignant liver lesions [15]. For our purpose of a local 
injection, the signal alterations due to enhanced suscepti-
bility in T2*-sequences in MRI was ideal and additionally 
not visible in CT scans. Our investigation showed that 
the anatomical reference in T2*-weighted imaging shows 
adequate mid-urethral accumulation in the target region 
(EUS).
Substantial research has looked into the feasibility, 
adverse effects and outcome of different interventions 
to treat SUI in women. Recently, a Cochrane systematic 
review compared different urethral injection therapies 
and concluded that the current evidence remains insuf-
ficient to guide practice [16]. They reported a similar 
outcome of periurethral versus transurethral outcomes 
regarding symptoms of SUI, whereas early complica-
tions tended to be higher in the periurethral group. The 
cost-effectiveness of urethral bulking agents compared 
to sling surgery was doubted during a longer follow-up 
period of 15  months. Burdzinska and colleagues com-
pared the accuracy between the transurethral and periu-
rethral route of intrasphincteric injections of autologous 
cellular suspensions in goats [17]. Their investigation 
revealed that 2/3 of all injections could be located in the 
urethral wall, while less than 1/5 were found inside EUS 
muscle structures. The main difference to our investiga-
tion was the fact that transurethral injections were per-
formed under endoscopic but no US guidance, which 
could be an explanation for the lower accuracy. Ameri-
can researches evaluated transurethral injections of bulk-
ing agents  (Macroplastique®) by 3D endo-vaginal US to 
describe location and distribution after the intervention 
[18]. By using US, they reported good precision at 3 and 
9 o’clock position of the EUS, but highly variable dis-
tances from the urethro-vesical junction. Blaganje et  al. 
demonstrated, that transurethral injections of autologous 
myoblasts through US guidance are feasible and reveals 
improvement of symptoms in combination with func-
tional electrical stimulation in more than 75% of female 
patients suffering from SUI [19]. Interestingly, Aicher 
and his group recently published a needle-free technique 
using a novel waterjet injection to deposit mesenchymal 
stromal cells into the EUS of fresh porcine urethrae [20]. 
The yield of viable cells was significantly higher than by 
injection through a William’s needle while assuring simi-
lar accuracy. Therefore, this novel approach could be a 
promising technique to deposit viable cells into the EUS 
in the future.
A limitation of this proof of concept is the post-mor-
tem character of our investigation. The injection and 
imaging in female cadavers may differ from in-vivo pro-
cedures and therefore results need to be interpreted with 
caution. Further, the use of nano-iron particles for MPC 
tracking was considered inappropriate for living humans, 
since macrophages tend to uptake and evacuate MPCs 
previously stained with iron oxide [21]. In addition, the 
two independent raters (radiological technologist and 
urologist) were not blinded to the treatment method, 
which could potentially induce assessor bias. However, 
the evaluation with the rating scale was performed in ref-
erence to the urethra as an anatomical structure and was 
the same in all three cadavers. Therefore, and according 
to our imaging series, the approach and the technique 
may be reliably used for the accurate deposition of inject-
ables through the transurethral route under US guidance.
Conclusion
Our US-guided injection technique for EUS applica-
tion is feasible and shows an adequate as well as precise 
accumulation of nano-iron particles in the desired tar-
get region, as confirmed by MRI. It may be applied as a 
simple approach to accurately deliver MPCs in the EUS 
for the regenerative treatment of female SUI in the near 
future.
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